ArticleCirculation2025
Ezh2 Shapes T Cell Plasticity to Drive Atherosclerosis.
Abstract read
In one paragraph
Article in Circulation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed.
- Post‑translational modifications in atherosclerosis: Roles, mechanisms and therapeutic potential (Review).International journal of molecular medicine · 2026Review
- Polycomb Repressive Complex 2 drives flow-sensitive endothelial states underlying vascular inflammation and disease.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Nanomaterials-Based Immunotherapy for Atherosclerosis.Small (Weinheim an der Bergstrasse, Germany) · 2026Review
- Functional Heterogeneity of Immune Cell Subpopulations in Atherosclerosis: From Basic Mechanisms to Precision Therapy.Reviews in cardiovascular medicine · 2026Review
- Overexpression of EZH2 is associated with clinicopathological parameters and poor prognosis in gliomas.Oncology letters · 2026Article
- Endothelial cannabinoid CB1 receptor deficiency reduces shear stress-induced arterial inflammation and lipid uptake.Nature communications · 2026Article
- Epigenetic regulation in atherosclerosis and its therapeutic potential.Nature reviews. Cardiology · 2026Review
- Single-cell T-cell landscape in atherosclerosis: implications for targeted therapy and beyond.Journal of translational medicine · 2026Review
- Unraveling Atherosclerosis through Multi-omics: Systematic Insights into the Unique Applications and Clinical Perspectives.Current atherosclerosis reports · 2026Review
- Histone Modifications in Cardiovascular Disease: Mechanisms and Therapeutic Opportunities.MedComm · 2026Review
- Endothelial-specific Ezh2 deficiency exacerbates blood-brain barrier dysfunction and neuroinflammation in sepsis-associated encephalopathy.Journal of neuroinflammation · 2026Article
- Oxidized LDL Induces Pro-Inflammatory Transcriptomic and Epigenomic Responses in Human CD4FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026Article
- Paligenosis: dual potential of mature cell plasticity in regeneration and tumorigenesis.MedScience · 2026Review
- Identification of shared oxidative stress related hub genes in NAFLD and atherosclerosis using bioinformatics and machine learning.Scientific reports · 2026Article
- Clinical retrospective study on serum sCD163 and CXCL10 in the immune microenvironment of carotid atherosclerosis: association with inflammatory cytokines, immune cell subsets, and disease progression.Frontiers in immunology · 2026Article
- Research progress on targeted regulatory proteins in the prevention and treatment of atherosclerosis.Frontiers in immunology · 2026Review
- Rational design and biological validation of EZH2/PD-L1 bifunctional inhibitors for colorectal cancer immunotherapy.Frontiers in immunology · 2026Article
- ApoB-specific CD4Frontiers in immunology · 2026Review
- Targeting the Th17/Treg axis: from immunological insights to therapeutic avenues in atherosclerosis.Frontiers in immunology · 2026Review
- Inflammatory drivers of carotid atherosclerosis: signaling pathways, immune cells, and plaque stability.Frontiers in cardiovascular medicine · 2026Review
Corrections and comments
- Commented on by
Authors and funding
22 authors.
Cecilia Assunta Bonfiglio *Institute for Cardiovascular Prevention (C.A.B., M.L., V.T., F.M.F., K.N., Y.W., V.B., I.A-K., Y.F.S.M., M.K., K.R., C.W., D.S., E.L., D.A.), Ludwig Maximilians Universität, Munich, Germany.ORCID 0000-0002-7422-0503
Michael Lacy *Institute for Cardiovascular Prevention (C.A.B., M.L., V.T., F.M.F., K.N., Y.W., V.B., I.A-K., Y.F.S.M., M.K., K.R., C.W., D.S., E.L., D.A.), Ludwig Maximilians Universität, Munich, Germany.
Vasiliki TriantafyllidouInstitute for Cardiovascular Prevention (C.A.B., M.L., V.T., F.M.F., K.N., Y.W., V.B., I.A-K., Y.F.S.M., M.K., K.R., C.W., D.S., E.L., D.A.), Ludwig Maximilians Universität, Munich, Germany.
Floriana Maria FarinaInstitute for Cardiovascular Prevention (C.A.B., M.L., V.T., F.M.F., K.N., Y.W., V.B., I.A-K., Y.F.S.M., M.K., K.R., C.W., D.S., E.L., D.A.), Ludwig Maximilians Universität, Munich, Germany.ORCID 0000-0002-5105-5672
Aleksandar JanjicAnthropology and Human Genetics, Faculty of Biology (A.J., W.E.), Ludwig Maximilians Universität, Munich, Germany.ORCID 0000-0001-7180-5381
Katrin NitzInstitute for Cardiovascular Prevention (C.A.B., M.L., V.T., F.M.F., K.N., Y.W., V.B., I.A-K., Y.F.S.M., M.K., K.R., C.W., D.S., E.L., D.A.), Ludwig Maximilians Universität, Munich, Germany.ORCID 0009-0001-8528-5548
Yuting WuInstitute for Cardiovascular Prevention (C.A.B., M.L., V.T., F.M.F., K.N., Y.W., V.B., I.A-K., Y.F.S.M., M.K., K.R., C.W., D.S., E.L., D.A.), Ludwig Maximilians Universität, Munich, Germany.
Venetia BaziotiInstitute for Cardiovascular Prevention (C.A.B., M.L., V.T., F.M.F., K.N., Y.W., V.B., I.A-K., Y.F.S.M., M.K., K.R., C.W., D.S., E.L., D.A.), Ludwig Maximilians Universität, Munich, Germany.
Irem Avcilar-KücükgözeInstitute for Cardiovascular Prevention (C.A.B., M.L., V.T., F.M.F., K.N., Y.W., V.B., I.A-K., Y.F.S.M., M.K., K.R., C.W., D.S., E.L., D.A.), Ludwig Maximilians Universität, Munich, Germany.
Yonara Freire Soares MarquesInstitute for Cardiovascular Prevention (C.A.B., M.L., V.T., F.M.F., K.N., Y.W., V.B., I.A-K., Y.F.S.M., M.K., K.R., C.W., D.S., E.L., D.A.), Ludwig Maximilians Universität, Munich, Germany.
Markus JoppichInstitute of Informatics (M.J.), Ludwig Maximilians Universität, Munich, Germany.ORCID 0000-0002-6665-8951
Mahadia KumkumInstitute for Cardiovascular Prevention (C.A.B., M.L., V.T., F.M.F., K.N., Y.W., V.B., I.A-K., Y.F.S.M., M.K., K.R., C.W., D.S., E.L., D.A.), Ludwig Maximilians Universität, Munich, Germany.ORCID 0009-0009-2565-598X
Katja RößInstitute for Cardiovascular Prevention (C.A.B., M.L., V.T., F.M.F., K.N., Y.W., V.B., I.A-K., Y.F.S.M., M.K., K.R., C.W., D.S., E.L., D.A.), Ludwig Maximilians Universität, Munich, Germany.
Anuroop Venkateswaran VenkatasubramaniDepartment of Molecular Biology (A.V.V., A.I.), Ludwig Maximilians Universität, Munich, Germany.ORCID 0000-0003-2119-8741
Axel ImhofDepartment of Molecular Biology (A.V.V., A.I.), Ludwig Maximilians Universität, Munich, Germany.
Wolfgang EnardAnthropology and Human Genetics, Faculty of Biology (A.J., W.E.), Ludwig Maximilians Universität, Munich, Germany.
Lars MaegdefesselDZHK (German Center for Cardiovascular Research), Partner Site Munich Heart Alliance, Germany (C.A.B., F.M.F., V.B., I.A-K., M.K., L.M., C.W., D.S., E.L., D.A.).ORCID 0000-0001-5228-2634
Menno de WintherDepartment of Medical Biochemistry, Amsterdam Institute for Cardiovascular Sciences, Atherosclerosis and Ischemic Syndromes, Amsterdam Institute for Infection and Immunity, Inflammatory Diseases, Amsterdam University Medical Center, The Netherlands (M.d.W.).ORCID 0000-0002-4038-6636
Christian WeberInstitute for Cardiovascular Prevention (C.A.B., M.L., V.T., F.M.F., K.N., Y.W., V.B., I.A-K., Y.F.S.M., M.K., K.R., C.W., D.S., E.L., D.A.), Ludwig Maximilians Universität, Munich, Germany.ORCID 0000-0003-4610-8714
Donato SantovitoInstitute for Cardiovascular Prevention (C.A.B., M.L., V.T., F.M.F., K.N., Y.W., V.B., I.A-K., Y.F.S.M., M.K., K.R., C.W., D.S., E.L., D.A.), Ludwig Maximilians Universität, Munich, Germany.ORCID 0000-0003-1811-4746
Esther Lutgens *Institute for Cardiovascular Prevention (C.A.B., M.L., V.T., F.M.F., K.N., Y.W., V.B., I.A-K., Y.F.S.M., M.K., K.R., C.W., D.S., E.L., D.A.), Ludwig Maximilians Universität, Munich, Germany.ORCID 0000-0002-2609-5744
Dorothee Atzler *Institute for Cardiovascular Prevention (C.A.B., M.L., V.T., F.M.F., K.N., Y.W., V.B., I.A-K., Y.F.S.M., M.K., K.R., C.W., D.S., E.L., D.A.), Ludwig Maximilians Universität, Munich, Germany.ORCID 0000-0002-6551-1544
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe activation and polarization of T cells play a crucial role in atherosclerosis and dictate athero-inflammation. The epigenetic enzyme EZH2 (enhancer of zeste homolog 2) mediates the H3K27me3 (trimethylation of histone H3 lysine 27) and is pivotal in controlling T cell responses.
methodsTo detail the role of T cell EZH2 in atherosclerosis, we used human carotid endarterectomy specimens to reveal plaque expression and geography of EZH2. Atherosclerosis-prone
results
conclusionsOur study uncovers the importance of T cell EZH2 in human and mouse atherosclerosis. Inhibition of Ezh2 in CD4
Indexed as
AtherosclerosisCD4-Positive T-LymphocytesCell PlasticityEnhancer of Zeste Homolog 2 ProteinAnimalsCD8-Positive T-LymphocytesDisease Models, AnimalHumansMaleMiceMice, Inbred C57BLMice, KnockoutMice, Knockout, ApoEPlaque, AtheroscleroticEnhancer of Zeste Homolog 2 ProteinEZH2 protein, humanEzh2 protein, mouseatherosclerosisepigenomicsEZH2natural killer T cellsT-lymphocytes
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.